• Greater Twin Cities: 715.294.4371

SURPASS Wins CRO Leadership Awards for a Second Year in a Row

May 13, 2015

Preclinical Research Leader, SURPASS, Wins CRO Leadership Awards by Life Science Leader Magazine for a Second Year in a Row.

Preclinical contract research organization Surpass wins CRO Leadership Awards            

OSCEOLA, WI and MOUNTAIN VIEW, CA ——Surpass, Inc. (“Surpass”), a leading preclinical contract research organization (CRO) servicing the medical device, pharma, and biotech industries received CRO Leadership Awards by Life Science Leader Magazine for the second year in a row in the areas of quality and regulatory. The awards are based on feedback from customers who use preclinical CRO services and industry research conducted by Nice Insight.

“We are honored to be recognized again this year as a leading preclinical contract research organization with impeccable quality and regulatory compliance,” said Surpass CEO, Dr. Tim Pelura. “These awards acknowledge Surpass’ strong commitment to excellence and delivering robust preclinical data to our clients. As an active member of the medical innovation continuum, we bring more to our client partners, consistently delivering high quality translational data and innovative solutions to help our clients advance their technologies and therapies into the marketplace.”

The CRO Leadership Awards were developed to assist life science executives and directors in their vetting process of CROs. The surveys and industry research for this award was managed by Nice Insight, the market research division of That’s Nice LLC. Nice Insight surveyed more than 2300 decision makers who use CRO services. From the list of more than 70 CROs who were profiled, the top 10% from each category were recognized with CRO Leadership Awards (A list of the 2015 CRO Leadership Award winners can be found on the CRO Leadership Awards website).

View full press release on iReach/PRNewswire.

About Surpass

At Surpass, our innovative approach to preclinical research goes beyond the ordinary. We’re changing the rules for a better way to get from concept to reality.

Surpass is a trusted, preclinical contract research organization with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our preclinical testing services in large in vivo models and human cadavers span the product development cycle (proof-of-concept, early feasibility, iterative prototype evaluations, human factors assessments, validation, pharmacokinetics (PK), GLP/safety studies, and physician/clinical bio-skills training).

At Surpass, we bring more to our client partners. Our award-winning Research Team provides insightful solutions and assistance every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.

Surpass’ breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, wound healing therapies, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, renal denervation systems, dermal patches, imaging systems, cardiac assist devices, and much more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful.

Connect with Surpass, Inc. on, LinkedIn, YouTube, TwitterFacebook, and Google+